Previous 10 | Next 10 |
2023-11-01 16:04:47 ET More on AtriCure AtriCure: Core Growth Markets Expanding, But Could Be Well Priced In Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure For further details s...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
AtriCure Inc. (ATRC) is expected to report $-0.3 for Q3 2023
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2023 Healthcare Conference. ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2023 financial results on Wednesday, N...
2023-09-04 12:21:00 ET Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. The investment bank noted that medtech growth slowed slightly in Q2, expanding by only 8.3% co...
2023-08-29 22:32:23 ET Summary AtriCure stock has been heavily sold off following its Q2 numbers, despite strong performance and a revised full-year outlook. The company has seen growth across all segments, with around 20% growth and profits posted at the adj. EBITDA line. Val...
2023-07-25 19:40:03 ET AtriCure, Inc. (ATRC) Q2 2023 Earnings Conference Call July 25, 2023 04:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick - CFO Conference Call Participants ...
2023-07-25 16:13:00 ET AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.11 beats by $0.19 . Revenue of $100.9M (+19.4% Y/Y) beats by $3.41M . For further details see: AtriCure GAAP EPS of -$0.11 beats by $0.19, revenue of $100.9M beats by $3.41M
Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvem...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...